RSV Treatment Landscape Expands with New Vaccines and Clinical Trials in 2024-2025
• Moderna's mRESVIA vaccine received MHRA approval in February 2025 for adults aged 60 and older, joining GSK's Arexvy and Pfizer's Abrysvo in the expanding RSV vaccine market.
• The FDA has mandated new safety warnings for RSV vaccines regarding Guillain-Barré Syndrome risk, highlighting ongoing safety monitoring efforts in early 2025.
• Multiple pharmaceutical companies including Sanofi, GSK, and Pfizer are conducting advanced clinical trials in 2024, focusing on various patient populations and novel therapeutic approaches.
Robust Influenza Pipeline Features 120+ Drug Candidates with Novel Approaches to Prevention and Treatment
DelveInsight's latest report reveals over 120 companies actively developing innovative therapies for influenza, including promising candidates like Moderna's mRNA-1010 vaccine and SAB Biotherapeutics' polyclonal antibody treatment. The pipeline showcases diverse therapeutic approaches, from next-generation vaccines to broad-spectrum antivirals, addressing critical needs in influenza prevention and treatment.
RSV Therapeutic Pipeline Shows Promise with Novel Therapies and Clinical Advancements
• Over 50 companies are actively developing more than 50 therapeutic options for Respiratory Syncytial Virus (RSV) treatment, indicating a robust pipeline.
• GSK's Arexvy vaccine demonstrated encouraging Phase III results, preventing lower respiratory tract disease (LRTD) in older adults across three RSV seasons.
• Merck's clesrovimab showed positive topline results in a Phase IIb/III trial as a preventive treatment for RSV in infants, highlighting potential for vulnerable populations.
© Copyright 2025. All Rights Reserved by MedPath